Fourteen research and development projects in the field of regenerative medicine are set to receive £8.5 million from the UK government as part of a drive to stimulate innnovation in the sector. The projects will be led by small and medium sized companies.
AstraZeneca Plc has announced plans to make 22 compounds available to medical researchers in the UK free of charge in a bid to promote more drug discovery. The compounds are not the focus of current research at the company.
A team of US scientists has reported interim results from a Phase 1 study of an autologous cardiac stem cell therapy which showed a substantial improvement in left ventricular systolic function in patients with heart disease. The findings appear in The Lancet.
Scientists working for Addex Pharmaceuticals Ltd of Switzerland have reported discovering an apparently novel interaction between two members of the G-protein coupled receptor (GPCR) family which may have implications for the treatment of diabetes.
The US Food and Drug Administration has issued new draft guidance to help manufacturers develop and seek approval for artificial pancreas device systems for type 1 diabetes. To date, no such device has been approved for marketing in the US.
CircuLite Inc, which is preparing to launch in Europe what is said to be the world’s smallest blood pump, has raised $30 million in a Series D financing from a syndicate of venture capitalists led by Forbion Capital Partners and new investor Ronald O. Perelman.
ArGEN-X BV of the Netherlands, which is developing monoclonal antibodies against human disease, has raised €27.5 million in a Series B round to support the development of its preclinical portfolio of products which are based on natural antibodies from the llama.
AstraZeneca Plc has announced the allocation of an additional $100 million to its venture capital arm, MedImmune Ventures, increasing the total capital under management to $400 million. The fund invests in private life science companies.
Sapiens Steering Brain Stimulation GmbH of Munich, Germany and Eindhoven, the Netherlands has raised €10 million in additional funding to support development of its brain stimulation technology for Parkinson’s disease and other neurological disorders.
Ipsen SA, the French specialist pharmaceutical company, has purchased a newly issued, $25 million convertible bond issue of Inspiration Biopharmaceuticals Inc of California to fulfill a milestone payment under a partnership agreement with the privately held US company.